Overview

Everolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow up

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The different mechanisms of action of Everolimus and cyclosporine suppress immune function in synergistic manner. Thus it is postulated that the use of Everolimus in combination with cyclosporine permits a significant cyclosporine dose reduction without loss of immunosuppressive activity in the clinical setting. The aim of the present study is to evaluate the evolution of renal function after initiation of Everolimus and minimalisation of CNI dose.
Phase:
Phase 4
Details
Lead Sponsor:
Rabin Medical Center
Treatments:
Everolimus
Sirolimus